Stents



< < Back to Main Page

Vendors



Abbott Vascular (TCT Booth: 1316)

PROMUS, First-Generation TAXUS Express Stents Perform Strongly in SPIRIT III Trial
September 21, 2009 — Boston Scientific Corp. today welcomed three-year results from the SPIRIT III clinical trial, which continue to reaffirm the proven...

Abbott's XIENCE V Cleared for Treatment of Coronary Artery Disease
Abbott Vascular's XIENCE V Everolimus-Eluting Coronary is indicated for improving coronary luminal diameter in patients with symptomatic heart disease...



Boston Scientific (TCT Booth: 716)

TAXUS Express Shows Superior to Bare-Metal Stents in AMI Patients at Two Years
September 29, 2009 – Boston Scientific Corp. Sept. 25 announced two-year follow-up data from the HORIZONS-AMI trial, is designed to determine the safety...

NEVO Sirolimus-Eluting Coronary Stent Has Significantly Less Chest Pain Than TAXUS Liberte
September 29, 2009 – At six months, patients receiving the NEVO Sirolimus-Eluting Coronary Stent reported significantly less chest pain than those receiving...

PROMUS, First-Generation TAXUS Express Stents Perform Strongly in SPIRIT III Trial
September 21, 2009 — Boston Scientific Corp. today welcomed three-year results from the SPIRIT III clinical trial, which continue to reaffirm the proven...

TAXUS Liberte DES Has Thinner Struts, More Flexibility
Boston Scientific Corp. offers its second-generation TAXUS Liberte Paclitaxel-Eluting Coronary Stent System, which has substantially thinner struts and...

Boston Scientific Offers PROMUS Everolimus-Eluting Coronary Stent System
Boston Scientific Corp. offers the PROMUS Everolimus-Eluting Coronary Stent System for the treatment of coronary artery disease. The PROMUS Stent is...

TAXUS Liberte Atom Coronary Stent Designed for 2.25 mm Vessels
Boston Scientific's TAXUS Liberte Atom Paclitaxel-Eluting Coronary Stent System is a next-generation drug-eluting stent (DES) specifically designed for...

TAXUS Liberte Long Offers Stent Length of 38 mm
Boston Scientific's TAXUS Liberte Long Paclitaxel-Eluting Coronary Stent System is designed for long lesions. At 38 mm, it is the longest available DES,...



C R Bard, Inc. (TCT Booth: 2221)

LifeStent FlexStar Offer Longest Peripheral Stents on the Market
C. R. Bard Inc. offers the LifeStent FlexStar and FlexStar XL Vascular Stent Systems, which are approved for the treatment of occlusive disease in native...



Cordis Corp. (TCT Booth: 610)

NEVO Sirolimus-Eluting Coronary Stent Has Significantly Less Chest Pain Than TAXUS Liberte
September 29, 2009 – At six months, patients receiving the NEVO Sirolimus-Eluting Coronary Stent reported significantly less chest pain than those receiving...

FDA Clears 2.25 mm CYPHER Sirolimus-Eluting Coronary Stent
September 22, 2009 – Cordis Corp. has received approval from the U.S. Food and Drug Administration (FDA) for a new, smaller version of the CYPHER Sirolimus-Eluting...

CYPHER Sirolimus-Eluting Stent Compares Well Against BMS at Six-Years
The CYPHER Sirolimus-eluting Coronary Stent offered by Cordis (a Johnson & Johnson company) was the first drug-eluting stent approved for the U.S. market...



Elixir Medical Corp.
Elixir Announces Positive First-In-Man Results for Three DES With Durable, Bioabsorbable Polymers
September 29, 2009 – Elixir Medical Corp. last week at TCT 2009 announced positive results from three multicenter first-in-man studies of its novolimus...

Elixir Medical Bioabsorbable Polymer Drug-Eluting Stents Featured at TCT 2009
September 17, 2009 – Elixir Medical Corp. said today its stent systems using bioabsorbable polymers will be featured in multiple sessions at the 21st annual...



Medtronic, Inc. (TCT Booth: 1911)

Study Shows Endeavor Stent Reduces Risk of Heart Attack, Cardiac Death
September 21, 2009 — Anticipating a change in the practice of interventional cardiology, Medtronic Inc. announced today that the latest findings from...

Endeavor Zotarolimus-Eluting Stent Offered for Treatment of Coronaries
Medtronic’s Endeavor Zotarolimus-Eluting Coronary Stent System is engineered for the treatment of coronary artery disease. Endeavor uses the Driver bare...



Prescient Healthcare Systems
vProtect Luminal Shield Discussed at TCT as New Treatment for Soft Coronary Lesions
September 18, 2009 – Following the recent CE mark certification of the vProtect Luminal Shield, the novel self-expanding coronary stent system will be...



Tryton Medical Inc. (TCT Booth: 630)

Tryton Celebrates 250th Implant of its Side Branch Stent System
September 15, 2009 – Tryton Medical Inc. said today its Tryton Side Branch Stent has been used in 250 procedures to treat atherosclerotic lesions at bifurcations...